Active Clinical Trials | Saint John’s Cancer Institute

What is a clinical trial?

Clinical trials are research studies designed to evaluate experimental treatments and procedures. Most breakthroughs in the diagnosis, treatment, and care of patients with cancer exist because of clinical trials.

Clinical trials have specific treatment plans with specific eligibility criteria. Criteria differ from study to study, and are frequently based on age, sex, type/stage of cancer, medical history, and current health status. Participation in a trial requires the ability to travel to the clinical trial center (in this case, the Saint John’s Cancer Institute).

Search for Open Clinical Trials at Saint John’s Cancer Institute.

What is it like to participate in a clinical trial?

Mark Perzley is interviewed by Saint John’s Cancer Institute in Santa Monica, California.

Saint John’s Experts Explain the Importance of Clinical Trials

Doctors, Kim Margolin, Santosh Kesari, Przemyslaw Twardowski, Parvin Peddi, Leland Foshag, and Emma Chacon deep dive into clinical trials and their significance to their patients and others.

Have questions?

For more information about any of our clinical trials, or general questions, please call our main hotline. See Clinical Trials FAQs for additional information.

Please call, 310-582-7448 to participate in a clinical trial

The clinical trials listed below represent active and enrolling trials. We implement, initiate, and oversee clinical trials here, at Saint John’s Cancer Institute, as well as other facilities in the Southern California region.

Search using key terms or filter by Centers of Excellence or by Lead Doctor.

Title	Center Name	Physician
A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment NCT ID : NCT05708352 Protocol Number : IIT2022-06-HU-DIET2TREAT Phase : 2 Location : Santa Monica, CA	Brain Tumors & Neuroscience	Akanksha Sharma, M.D.
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer NCT ID : 05894239 Protocol Number : WO44263 Phase : 3 Location : Burbank, California	Breast Surgery and Oncology	Erwin Grussie, MD
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% NCT ID : 06170788 Protocol Number : MK2870-007 Phase : 3 Location : Burbank, California	Thoracic	Karlton Wong, MD
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial NCT ID : 05554380 Protocol Number : EAY191-S3 Phase : 2 Location : Santa Monica, CA	Multiple Tumors	Revo Basho, M.D.
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial NCT ID : 05554354 Protocol Number : EAY191-N2 Phase : 2 Location : Santa Monica, CA	Breast Surgery and Oncology	Revo Basho, M.D.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT ID : 05564377 Protocol Number : EAY191 Phase : 2 Location : Santa Monica, CA	Breast Surgery and Oncology Gynecologic Oncology	Revo Basho, M.D.
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial NCT ID : 05710328 Protocol Number : EA1211 Phase : 2 Location : Santa Monica, Ca	Breast Surgery and Oncology	Parvin Peddi, M.D.
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma NCT ID : 05529316 Protocol Number : C-800-23 Phase : 2 Location : Santa Monica, Ca	Melanoma, Skin and Soft Tissue Tumors	Kim Margolin, M.D.
Safety and Efficacy Study of NUV-868 Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NCT ID : 05252390 Protocol Number : NUV-868-01 Phase : 1/2 Location : Santa Monica, Ca	Urology and Urologic Oncology	Mitchell Gross, M.D.
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery NCT ID : 05608291 Protocol Number : R3767-ONC-2055 Phase : 3 Location : Saint John's Cancer Institute	Melanoma, Skin and Soft Tissue Tumors	Kim Margolin, M.D.
A Beta-only IL-2 Immunotherapy Study (ABILITY-1) NCT ID : 05086692 Protocol Number : MDNA 11-01 Phase : 1/2 Location : Saint John's Cancer Institute	All Solid Tumors	Przemyslaw Twardowski, M.D.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2) NCT ID : 04658862 Protocol Number : 17000139BLC3001 (Sunshine 2) Phase : 3 Location : Saint John's Cancer Institute	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
A Study of ARV-766 Given by Mouth in Men With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on Prior Approved Systemic Therapies NCT ID : 05067140 Protocol Number : ARV-766mCRPC-101 Phase : 1/2 Location : Saint John's Cancer Institute	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer NCT ID : 03972657 Protocol Number : R5678-ONC-1879 Phase : 1/2 Location : Saint John's Cancer Institute	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab NCT ID : 05812807 Protocol Number : A012103 Phase : 3 Location : Saint John's Cancer Institute	Breast Surgery and Oncology	Parvin Peddi, M.D.
(SPARTA) APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors NCT ID : 03175224 Protocol Number : SPARTA APL-101 Phase : 2 Location : Saint John's Cancer Institute	All Solid Tumors	Akanksha Sharma, M.D.
A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors) NCT ID : 05155332 Protocol Number : 1456-0001 Phase : 1 Location : Saint John's Cancer Institute	All Solid Tumors	Naveed Wagle, M.D.
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION) NCT ID : 05580562 Protocol Number : ONC201-108 Phase : 3 Location : Saint John's Cancer Institute	Brain Tumors & Neuroscience	Akanksha Sharma, M.D.
Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions NCT ID : 05068726 Protocol Number : GE-280-401 Phase : 4 Location : Saint John's Cancer Institute	Breast Surgery and Oncology	Parvin Peddi, M.D.
Metastatic Castration-Resistant Prostate Cancer (CAPItello-280) NCT ID : 05348577 Protocol Number : D361EC00001 (CAPItello-280) Phase : 3 Location : Santa Monica, Ca	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
Locally advanced or metastatic solid tumors: A Phase I Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects with Advanced Cancer NCT ID : 03860272 Protocol Number : C-800-01 Phase : 1 Location : Santa Monica, CA	All Solid Tumors Multiple Tumors	Kim Margolin, M.D.
Melanoma, Merkel Cell, Renal Cell NSCLC (iPREDICT) NCT ID : 05013099 Protocol Number : IAB-CD8-203 Phase : 2b Location : Santa Monica, CA	All Solid Tumors	Kim Margolin, M.D.
Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT. NCT ID : 03488693 Protocol Number : CCTGMA.39 Phase : 3 Location : Santa Monica, CA	Breast Surgery and Oncology	Janie Grumley, M.D.
All Solid Metastatic or Advanced Tumors: TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer NCT ID : 04246671 Protocol Number : TAEK-VAC-HerBy-001 Phase : 1 Location : Saint John's Cancer Institute	All Solid Tumors	Naveed Wagle, M.D.
Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer NCT ID : 04958785 Protocol Number : GS-US-586-6144 Phase : 2 Location : Saint John's Cancer Institute	Breast Surgery and Oncology	Parvin Peddi, M.D.
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study NCT ID : 05568472 Protocol Number : SWOG-S2010 Phase : 3 Location : Saint John's Cancer Institute	Breast Surgery and Oncology	Janie Grumley, M.D.
White Button Mushroom Supplement for Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Naïve Patients NCT ID : 04519879 Protocol Number : White Button Mushroom Phase : 2 Location : Santa Monica, CA	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies NCT ID : 04566393 Protocol Number : ULI-EAP-100 Phase : N/A Location : Santa Monica, CA	Multiple Tumors	Naveed Wagle, M.D.
Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas NCT ID : 04617002 Protocol Number : ONC028 Phase : N/A Location : Santa Monica, CA	Brain Tumors & Neuroscience	Akanksha Sharma, M.D.
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma NCT ID : 05561374 Protocol Number : OKN-007-OL Phase : 1 Location : Saint John's Cancer Institute	Brain Tumors & Neuroscience	Naveed Wagle, M.D.
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE) NCT ID : N/A Protocol Number : CBI_2019_SLNBprosp_001 Phase : N/A Location : Santa Monica, CA	Melanoma, Skin and Soft Tissue Tumors	Richard Essner, M.D.
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania) NCT ID : 04873362 Protocol Number : WO42633 Phase : 3 Location : Disney Family Cancer Center	Breast Surgery and Oncology	Erwin Grussie, M.D.